KIFFIK Biomedical and Duracell U.S. Operations, Inc. agreed to assess integrating Duracell batteries into KIFFIK biomonitoring devices, such as health monitors that detect biomarkers.
KIFFIK Biomedical announced an alliance with HekaBio K.K. to expand access to interstitial fluid across Japan and Asia-Pacific markets. The K-EXP platform provides direct access to interstitial fluid for molecular measurement at the source.
KIFFIK Biomedical partnered with Beacon MedTech Solutions to deliver the K-EXP platform. The clinical device is expected to be available in the second half of 2026, with scalable production of its next-generation device planned to begin in mid-2027.
KIFFIK provides direct access to interstitial fluid (ISF), the molecular environment surrounding living cells. The page says ISF can make biology visible earlier than blood measurements taken after systemic circulation.
The company collects personal and non-personal information, including anonymous usage data, demographic information, referring and exit pages and URLs, platform types, and preferences submitted or generated from submitted data.
